Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA)

Inclusion Criteria: * Male or female, age \>/=55 years * Best corrected visual acuity of 20/20 - 20/400 in the study eye * Best corrected visual acuity of hand motion or better in the non-study eye * Clinical diagnosis of geographic atrophy secondary to non-exudative age-related macular degeneration in at least one eye (study eye) * Geographic atrophy lesions of ≥ 0.5 and ≤ 7.0 MPS disc areas Exclusion Criteria: * History of or active presence of choroidal neovascularization secondary to exudative age-related macular degeneration in the study eye * History of or active presence of choroidal neovascularization secondary to exudative age-related macular degeneration in the non-study eye requiring any treatment within 12 months prior to Day 0 or expected to require treatment for the duration of the study * Prior treatment for non-exudative age-related macular degeneration * Current or previous history of treatment of the study eye with any tetracycline derivative for any ocular condition. * History of vitreoretinal surgery, corneal transplant, or laser photocoagulation in the study eye * Any intraocular or periocular surgery within 90 days prior to Day 0 in the study eye. * History of any hypersensitivity to tetracycline components * Use of a tetracycline derivative therapy for a concurrent systemic or ocular disorder within 90 days of Day 0 * History of sensitivity to the sun